TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) CEO David P. Southwell acquired 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The shares were purchased at an average cost of $3.59 per share, for a total transaction of $89,750.00. Following the completion of the acquisition, the chief executive officer […]